TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Dose-escalating Study of the Safety and Pharmacokinetics of GSK679586A in Healthy Volunteers and Mild Asthmatics.
Brief Summary: This is a two part study. Part I is designed to test single doses of GSK678586A in healthy volunteers. Part II is designed to test repeat doses (two doses) of GSK679586A in patients with mild asthma. Both parts are designed to investigate the safety, tolerability and the way the body absorbs GSK679586A when given by intravenous infusion (through a vein in your arm).


Options:
A: Arm Label: MEMP1972A 150 mg; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A | Arm Label: MEMP1972A 300 mg; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A | Arm Label: MEMP1972A 450 mg; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: MEMP1972A; Assigned to Arm(s): MEMP1972A 300 mg | Intervention Type: DRUG; Name: MEMP1972A; Assigned to Arm(s): MEMP1972A 450 mg | Intervention Type: DRUG; Name: MEMP1972A; Assigned to Arm(s): MEMP1972A 150 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: GSK679586 | Intervention Type: DRUG; Name: GSK679586; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Mepolizumab Arm; Type: EXPERIMENTAL; Interventions: Biological: Mepolizumab | Intervention Type: BIOLOGICAL; Name: Mepolizumab; Assigned to Arm(s): Mepolizumab Arm
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: MEDI-563 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: MEDI-563 | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Comp. | Arm Label: 5; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: MEDI-563; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: MEDI-563; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Placebo Comp.; Assigned to Arm(s): 4 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 5

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Dose-escalating Study of the Safety and Pharmacokinetics of GSK679586A in Healthy Volunteers and Mild Asthmatics.
Brief Summary: This is a two part study. Part I is designed to test single doses of GSK678586A in healthy volunteers. Part II is designed to test repeat doses (two doses) of GSK679586A in patients with mild asthma. Both parts are designed to investigate the safety, tolerability and the way the body absorbs GSK679586A when given by intravenous infusion (through a vein in your arm).


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: GSK679586 | Intervention Type: DRUG; Name: GSK679586; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Mepolizumab 750mg; Type: ACTIVE_COMPARATOR; Interventions: Biological: Mepolizumab 750 | Arm Label: Mepolizumab 250mg; Type: ACTIVE_COMPARATOR; Interventions: Biological: Mepolizumab 250 | Arm Label: Mepolizumab 75mg; Type: ACTIVE_COMPARATOR; Interventions: Biological: Mepolizumab 75 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo saline | Intervention Type: BIOLOGICAL; Name: Mepolizumab 750; Assigned to Arm(s): Mepolizumab 750mg | Intervention Type: BIOLOGICAL; Name: Mepolizumab 250; Assigned to Arm(s): Mepolizumab 250mg | Intervention Type: BIOLOGICAL; Name: Mepolizumab 75; Assigned to Arm(s): Mepolizumab 75mg | Intervention Type: DRUG; Name: Placebo saline; Assigned to Arm(s): Placebo
C: Arm Label: Omalizumab (Xolair) + Conventional Therapy; Type: EXPERIMENTAL; Interventions: Biological: omalizumab | Arm Label: Placebo + Conventional Therapy; Type: PLACEBO_COMPARATOR; Interventions: Biological: omalizumab placebo | Intervention Type: BIOLOGICAL; Name: omalizumab; Assigned to Arm(s): Omalizumab (Xolair) + Conventional Therapy | Intervention Type: BIOLOGICAL; Name: omalizumab placebo; Assigned to Arm(s): Placebo + Conventional Therapy
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: CAT-354 150 mg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 150 mg | Arm Label: CAT-354 300 mg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 300 mg | Arm Label: CAT-354 600 mg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 600 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: CAT-354 150 mg; Assigned to Arm(s): CAT-354 150 mg | Intervention Type: BIOLOGICAL; Name: CAT-354 300 mg; Assigned to Arm(s): CAT-354 300 mg | Intervention Type: BIOLOGICAL; Name: CAT-354 600 mg; Assigned to Arm(s): CAT-354 600 mg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2, Single-Center, Placebo-Controlled Study of the Effects of Combined Administration of Vasopressin, Methylprednisolone, and Epinephrine During Cardiopulmonary Resuscitation on Survival After Cardiac Arrest
Brief Summary: A randomized controlled trial did not show benefit of vasopressin versus epinephrine in inhospital cardiac arrest. Preceding laboratory data suggest that combined vasopressin and epinephrine ensure long-term survival and neurologic recovery. Also, postresuscitation abnormalities mimic severe sepsis. The investigators hypothesized that combined vasopressin and epinephrine during cardiopulmonary resuscitation (CPR), and steroid supplementation during and after (when required) CPR may improve survival in cardiac arrest.


Options:
A: Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Epinephrine, Placebo | Arm Label: Study Group; Type: EXPERIMENTAL; Interventions: Drug: Vasopressin, Epinephrine, and Steroids | Intervention Type: DRUG; Name: Vasopressin, Epinephrine, and Steroids; Assigned to Arm(s): Study Group | Intervention Type: DRUG; Name: Placebo, Epinephrine, Placebo; Assigned to Arm(s): Control Group
B: Intervention Type: DRUG; Name: epinephrine (1 mg/1 mL); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: arginine-vasopressin (40 UI/2 mL); Assigned to Arm(s): N/A
C: Arm Label: IV yes; Type: EXPERIMENTAL; Interventions: Drug: Epinephrine, Device: Intravenous needle, Drug: Atropine, Drug: Amiodarone | Arm Label: IV no; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Epinephrine; Assigned to Arm(s): IV yes | Intervention Type: DEVICE; Name: Intravenous needle; Assigned to Arm(s): IV yes | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): IV yes | Intervention Type: DRUG; Name: Amiodarone; Assigned to Arm(s): IV yes
D: Arm Label: Active Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Quality improvement | Arm Label: Control Hospitals; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Quality improvement; Assigned to Arm(s): Active Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PACE-iDP: An Intervention for Youth at Risk for Diabetes
Brief Summary: This randomized control study (sponsored by the NIH, NIDDK) is aimed at reducing BMI in overweight adolescents at risk for the development of type 2 diabetes. The study will examine whether an integrated primary care, web and cell-phone-based intervention can produce initial and sustained improvements in anthropometric, behavioral, metabolic, and physiological outcomes in overweight adolescents. The primary goal is to reduce BMI (Body Mass Index)in overweight adolescents.


Options:
A: Intervention Type: BEHAVIORAL; Name: Low glycemic index diet; Assigned to Arm(s): N/A
B: Arm Label: Next.Step; Type: EXPERIMENTAL; Interventions: Other: Next.Step - e-therapeutic intervention program | Arm Label: Standard protocol; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard treatment protocol | Intervention Type: OTHER; Name: Next.Step - e-therapeutic intervention program; Assigned to Arm(s): Next.Step | Intervention Type: OTHER; Name: Standard treatment protocol; Assigned to Arm(s): Standard protocol
C: Arm Label: W82GO; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: W82GO | Arm Label: Smartphone; Type: EXPERIMENTAL; Interventions: Device: smartphone application | Intervention Type: BEHAVIORAL; Name: W82GO; Assigned to Arm(s): W82GO | Intervention Type: DEVICE; Name: smartphone application; Assigned to Arm(s): Smartphone
D: Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention - Web; Type: EXPERIMENTAL; Interventions: Behavioral: Weekly access to interactive web site | Arm Label: Intervention - Group; Type: EXPERIMENTAL; Interventions: Behavioral: Group | Arm Label: Intervention - Cell Phone; Type: EXPERIMENTAL; Interventions: Behavioral: Cell Phone | Intervention Type: BEHAVIORAL; Name: Cell Phone; Assigned to Arm(s): Intervention - Cell Phone | Intervention Type: BEHAVIORAL; Name: Weekly access to interactive web site; Assigned to Arm(s): Intervention - Web | Intervention Type: BEHAVIORAL; Name: Group; Assigned to Arm(s): Intervention - Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PACE-iDP: An Intervention for Youth at Risk for Diabetes
Brief Summary: This randomized control study (sponsored by the NIH, NIDDK) is aimed at reducing BMI in overweight adolescents at risk for the development of type 2 diabetes. The study will examine whether an integrated primary care, web and cell-phone-based intervention can produce initial and sustained improvements in anthropometric, behavioral, metabolic, and physiological outcomes in overweight adolescents. The primary goal is to reduce BMI (Body Mass Index)in overweight adolescents.


Options:
A: N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-Directed Weight Loss Program | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Call-Center Directed (CCD) Weight Loss Program | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: In-Person Directed (IPD) Weight Loss Program | Intervention Type: BEHAVIORAL; Name: Call-Center Directed (CCD) Weight Loss Program; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: In-Person Directed (IPD) Weight Loss Program; Assigned to Arm(s): 3 | Intervention Type: BEHAVIORAL; Name: Self-Directed Weight Loss Program; Assigned to Arm(s): 1
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Device: placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: VISITS + PDA-FIT system | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Device: PDA-FIT System + telephone follow-up | Intervention Type: DEVICE; Name: placebo; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: VISITS + PDA-FIT system; Assigned to Arm(s): 2 | Intervention Type: DEVICE; Name: PDA-FIT System + telephone follow-up; Assigned to Arm(s): 3
D: Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention - Web; Type: EXPERIMENTAL; Interventions: Behavioral: Weekly access to interactive web site | Arm Label: Intervention - Group; Type: EXPERIMENTAL; Interventions: Behavioral: Group | Arm Label: Intervention - Cell Phone; Type: EXPERIMENTAL; Interventions: Behavioral: Cell Phone | Intervention Type: BEHAVIORAL; Name: Cell Phone; Assigned to Arm(s): Intervention - Cell Phone | Intervention Type: BEHAVIORAL; Name: Weekly access to interactive web site; Assigned to Arm(s): Intervention - Web | Intervention Type: BEHAVIORAL; Name: Group; Assigned to Arm(s): Intervention - Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Comparative Phase III, 2-center Study of Hexvix Fluorescence Cystoscopy and Standard Cystoscopy in Patients With Non-invasive Bladder Cancer
Brief Summary: The main objective of the study is to compare the 1-year recurrence rate of Hexvix assisted Transuretheral Resection of the Bladder (TURB) to standard white light TURB in patients with suspicion of non-invasive bladder cancer.

The hypothesis is to test whether the 1-year recurrence rate is different with Hexvix assisted TURB compared to standard white light TURB.


Options:
A: Arm Label: Standard White Light Cystoscopy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard white light cystoscopy | Arm Label: Standard White Light and Hexvix Fluorescence Cystoscopy; Type: EXPERIMENTAL; Interventions: Drug: Hexvix, Procedure: Standard white light cystoscopy | Intervention Type: DRUG; Name: Hexvix; Assigned to Arm(s): Standard White Light and Hexvix Fluorescence Cystoscopy | Intervention Type: PROCEDURE; Name: Standard white light cystoscopy; Assigned to Arm(s): Standard White Light Cystoscopy, Standard White Light and Hexvix Fluorescence Cystoscopy
B: Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: mitomycin C; Assigned to Arm(s): N/A
C: Arm Label: Hexvix cystoscopy group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hexvix | Arm Label: White light; Type: OTHER; Interventions: Other: Standard white light cystoscopy | Intervention Type: DRUG; Name: Hexvix; Assigned to Arm(s): Hexvix cystoscopy group | Intervention Type: OTHER; Name: Standard white light cystoscopy; Assigned to Arm(s): White light
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Gemcitabine | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation
Brief Summary: The trial seeks to determine if apixaban, an investigational anticoagulant (blood-thinner) is as effective as standard therapy (warfarin) in preventing stroke and systemic embolism in subjects with atrial fibrillation and risk factors for stroke.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: apixaban | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: apixaban; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor 90 mg | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor 60 mg | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ticagrelor Placebo | Intervention Type: DRUG; Name: Ticagrelor 90 mg; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Ticagrelor 60 mg; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Ticagrelor Placebo; Assigned to Arm(s): 3
C: Arm Label: idarucizumab; Type: EXPERIMENTAL; Interventions: Drug: idarucizumab | Intervention Type: DRUG; Name: idarucizumab; Assigned to Arm(s): idarucizumab
D: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban/Placebo | Arm Label: 003; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban/Placebo; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): 001

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation
Brief Summary: The trial seeks to determine if apixaban, an investigational anticoagulant (blood-thinner) is as effective as standard therapy (warfarin) in preventing stroke and systemic embolism in subjects with atrial fibrillation and risk factors for stroke.


Options:
A: Arm Label: Dabigatran Etexilate 110mg; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran Etexilate 110mg, Drug: Clopidogrel or Ticagrelor | Arm Label: Dabigatran Etexilate 150mg; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran Etexilate 150mg, Drug: Clopidogrel or Ticagrelor | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin 3mg, Drug: Aspirin, Drug: Clopidogrel or Ticagrelor, Drug: Warfarin 5mg, Drug: Warfarin 1mg | Intervention Type: DRUG; Name: Dabigatran Etexilate 110mg; Assigned to Arm(s): Dabigatran Etexilate 110mg | Intervention Type: DRUG; Name: Warfarin 3mg; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Dabigatran Etexilate 150mg; Assigned to Arm(s): Dabigatran Etexilate 150mg | Intervention Type: DRUG; Name: Clopidogrel or Ticagrelor; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Clopidogrel or Ticagrelor; Assigned to Arm(s): Dabigatran Etexilate 110mg | Intervention Type: DRUG; Name: Warfarin 5mg; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Clopidogrel or Ticagrelor; Assigned to Arm(s): Dabigatran Etexilate 150mg | Intervention Type: DRUG; Name: Warfarin 1mg; Assigned to Arm(s): Warfarin
B: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban, Drug: Matching placebo for Rivaroxaban arm (Warfarin placebo) | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin, Drug: Matching placebo for Warfarin arm (Rivaroxaban placebo) | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Matching placebo for Rivaroxaban arm (Warfarin placebo); Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Matching placebo for Warfarin arm (Rivaroxaban placebo); Assigned to Arm(s): Warfarin
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: apixaban | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: apixaban; Assigned to Arm(s): 2
D: Arm Label: Prasugrel; Type: EXPERIMENTAL; Interventions: Drug: Prasugrel | Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Intervention Type: DRUG; Name: Prasugrel; Assigned to Arm(s): Prasugrel | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation
Brief Summary: The trial seeks to determine if apixaban, an investigational anticoagulant (blood-thinner) is as effective as standard therapy (warfarin) in preventing stroke and systemic embolism in subjects with atrial fibrillation and risk factors for stroke.


Options:
A: Arm Label: Dabigatran dose 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 2 | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: Dabigatran dose 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 1 | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Dabigatran dose 1; Assigned to Arm(s): Dabigatran dose 1 | Intervention Type: DRUG; Name: Dabigatran dose 2; Assigned to Arm(s): Dabigatran dose 2
B: Arm Label: Warfarin/placebo edoxaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin tablets, Drug: placebo edoxaban | Arm Label: high dose edoxaban/placebo warfarin; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban tablets (high dose regimen-60mg), Drug: placebo warfarin | Arm Label: low dose edoxaban/placebo warfarin; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban tablets (low dose regimen-30mg), Drug: placebo warfarin | Intervention Type: DRUG; Name: warfarin tablets; Assigned to Arm(s): Warfarin/placebo edoxaban | Intervention Type: DRUG; Name: Edoxaban tablets (high dose regimen-60mg); Assigned to Arm(s): high dose edoxaban/placebo warfarin | Intervention Type: DRUG; Name: Edoxaban tablets (low dose regimen-30mg); Assigned to Arm(s): low dose edoxaban/placebo warfarin | Intervention Type: DRUG; Name: placebo warfarin; Assigned to Arm(s): high dose edoxaban/placebo warfarin, low dose edoxaban/placebo warfarin | Intervention Type: DRUG; Name: placebo edoxaban; Assigned to Arm(s): Warfarin/placebo edoxaban
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: apixaban | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: apixaban; Assigned to Arm(s): 2
D: Arm Label: AF Clinic; Type: EXPERIMENTAL; Interventions: Other: AF Clinic | Arm Label: Care as Usual; Type: ACTIVE_COMPARATOR; Interventions: Other: Care as Usual | Intervention Type: OTHER; Name: AF Clinic; Assigned to Arm(s): AF Clinic | Intervention Type: OTHER; Name: Care as Usual; Assigned to Arm(s): Care as Usual

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects With Nonvalvular Atrial Fibrillation
Brief Summary: The trial seeks to determine if apixaban, an investigational anticoagulant (blood-thinner) is as effective as standard therapy (warfarin) in preventing stroke and systemic embolism in subjects with atrial fibrillation and risk factors for stroke.


Options:
A: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban, Drug: Matching placebo for Rivaroxaban arm (Warfarin placebo) | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin, Drug: Matching placebo for Warfarin arm (Rivaroxaban placebo) | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Matching placebo for Rivaroxaban arm (Warfarin placebo); Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Matching placebo for Warfarin arm (Rivaroxaban placebo); Assigned to Arm(s): Warfarin
B: Arm Label: Dabigatran etexilate; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran etexilate | Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Dabigatran etexilate; Assigned to Arm(s): Dabigatran etexilate
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: apixaban | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: apixaban; Assigned to Arm(s): 2
D: Arm Label: dabigatran etexilate 150 mg; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg | Arm Label: warfarin (INR 2-3); Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin (INR 2-3) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg; Assigned to Arm(s): dabigatran etexilate 150 mg | Intervention Type: DRUG; Name: warfarin (INR 2-3); Assigned to Arm(s): warfarin (INR 2-3)

Answer: C